JINGXIN(SZ:002020) Sou Hu Cai Jing·2026-02-27 02:47Core Viewpoint - Zhejiang Jingxin Pharmaceutical Co., Ltd. has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor, focusing on innovation-driven pharmaceutical development in central nervous system and cardiovascular diseases [3]. Financial Performance - Projected revenues for Jingxin Pharmaceutical are expected to be RMB 4 billion in 2023 and RMB 4.16 billion in 2024, with net profits of RMB 623 million and RMB 719 million respectively [3][5]. - For the first ten months of 2025, the company reported revenues of RMB 3.34 billion, a decrease of 2.74% year-on-year, while net profit increased by 12.69% to RMB 629 million [3][5]. Business Model - The company combines the commercialization of existing products with ongoing development of its product pipeline, which includes pharmaceuticals (generic drugs, innovative drugs, traditional Chinese medicine, and biological products), active pharmaceutical ingredients, and medical devices [3]. Shareholding Structure - The company is controlled by a group of shareholders led by Executive Director and Chairman Lü Gang, who holds approximately 20.77% of the shares, along with Jingxin Holdings and Jinzhihua Investment [6]. Leadership - Lü Gang, aged 63, has been with the company since 1999 and has held various leadership roles, including Chairman and General Manager, responsible for strategic planning and overall operations [8]. - Lü Jiaqi, Lü Gang's daughter, joined the company in 2020 and is responsible for managing the pharmaceutical formulation export department [9][10].